NEUP Stock — Neuphoria Therapeutics Inc.: Cash, EV, Pipeline

Share price

$3.70

Market cap

$20.0M

Cash

$19.4M

Enterprise value

$0.6M

Balance sheet

Cash	$19.4M
Debt	$0.0M
Net cash	$19.4M
Enterprise value	$0.6M
Basic shares	5.4M shares
Fully diluted shares	6.6M shares
Fully diluted market cap	$24.5M
Cash per share	$3.60

Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.

Price history

Loading NEUP daily closes…

Loading price history…

Pipeline assets

BNC210

Phase 2 · Active Modality: small molecule

Target alpha7 receptor

Indications

Post-traumatic stress disorder (PTSD) (Phase 2)

Status note Lead product candidate; oral, proprietary, selective negative allosteric modulator (NAM) of the alpha7 receptor for chronic PTSD treatment. Program PAUSED (BNC210 SAD program discontinued; PTSD program paused) while the company undertakes a comprehensive strategic review: all but one employee terminated, facility leases terminated, R&D activities cancelled or paused, seeking a merger/partner. Planned Phase 3 in PTSD on hold.

Merck-partnered cognitive dysfunction program (unnamed)

Phase 2 · Active

Target α7 nAChR

Partnerships Merck & Co: research and license agreement to develop compounds targeting cognitive dysfunction in Alzheimer's and other CNS conditions; $15M milestone received March 2025 on first dosing in a Phase II clinical trial

Indications

Cognitive dysfunction associated with Alzheimer's disease (Phase 2)

Status note Out-licensed program; development conducted by the collaboration partner. Filing states no candidate name.

Per-asset detail extracted from the 10-Q filed 2026-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	47,443	no change	0.03%	2026-08-14
ADAR1 Capital Management	30,000	no change	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

NEUP — Neuphoria Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders